WALTHAM, Mass., Aug. 10, 2017 /PRNewswire/ -- Thermo Fisher
Scientific Inc. (NYSE: TMO) announced that it has priced an
offering of $1.5 billion aggregate
principal amount of the following notes:
- $750 million aggregate principal
amount of its 3.200% senior notes due 2027, at an issue price of
99.263% of their principal amount and
- $750 million aggregate principal
amount of its 4.100% senior notes due 2047, at an issue price of
98.825% of their principal amount.
The issuance of the notes is expected to close on August 14, 2017, subject to customary closing
conditions. The notes will pay interest on a semi-annual basis.
Thermo Fisher intends to use all
of the net proceeds of the offering to fund a portion of the
consideration payable for its acquisition of Patheon N.V. (NYSE:
PTHN), including the repayment of indebtedness of Patheon N.V. to
be assumed by Thermo Fisher. As
previously announced, Thermo Fisher
now expects to complete the transaction around the end of the third
quarter of 2017, subject to the satisfaction of customary closing
conditions, including the receipt of applicable regulatory
approvals and completion of Thermo
Fisher's tender offer to acquire all of the issued and
outstanding shares of Patheon N.V.
The joint book-running managers for the offering are Goldman
Sachs & Co. LLC, Citigroup Global Markets Inc., J.P. Morgan
Securities LLC and Merrill Lynch, Pierce, Fenner & Smith
Incorporated.
The offering is being made pursuant to an effective registration
statement on Form S-3, as amended by the post-effective amendment
thereto (including a prospectus), filed with the U.S. Securities
and Exchange Commission (the "SEC"). Prospective investors should
read the prospectus forming a part of that registration statement
and the prospectus supplement related to the offering and the other
documents that Thermo Fisher has
filed with the SEC for more complete information about Thermo Fisher and this offering. These documents
are available at no charge by visiting EDGAR on the SEC website at
www.sec.gov. Alternatively, Thermo
Fisher, the underwriters or any dealer participating in this
offering will arrange to send you the prospectus if you request it
by calling one of the following:
- Goldman Sachs & Co. LLC toll-free at 1-866-471-2526
- Citigroup Global Markets Inc. toll-free at 1-800-831-9146
- J.P. Morgan Securities LLC collect at 1-212-834-4533
- Merrill Lynch, Pierce, Fenner & Smith Incorporated
toll-free at 1-800-294-1322
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy the notes, nor shall there be any
offer, solicitation or sale of the notes in any jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
the registration or qualification under the securities laws of any
such jurisdiction.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including, but not limited to, statements about the company's
intended use of proceeds and the anticipated timing of the closing
of the Patheon acquisition. These statements involve a number
of risks and uncertainties that could cause actual results to
differ materially from currently anticipated results, including
risks and uncertainties relating to capital markets conditions and
completion of the offering. Additional important factors and
information regarding Thermo
Fisher's business that could cause actual results to differ
materially from those indicated by such forward-looking statements
are set forth in the prospectus and prospectus supplement dated
August 10, 2017 related to the
offering, which is on file with the SEC and available in the
"Investors" section of Thermo
Fisher's website under the heading "SEC Filings," and the
documents incorporated by reference into the prospectus and
prospectus supplement. While Thermo
Fisher may elect to update forward-looking statements at
some point in the future, Thermo
Fisher specifically disclaims any obligation to do so, even
if circumstances change and, therefore, you should not rely on
these forward-looking statements as representing Thermo Fisher's views as of any date subsequent
to today.
Media Contact Information:
Karen Kirkwood
Phone: 781-622-1306
E-mail: karen.kirkwood@thermofisher.com
or
Investor Contact Information:
Ken Apicerno
Phone: 781-622-1294
E-mail: ken.apicerno@thermofisher.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/thermo-fisher-scientific-prices-offering-of-senior-notes-300503102.html
SOURCE Thermo Fisher Scientific Inc.
